19 March 2024>: Original Paper
Long-Term Outcomes with Prolonged-Release Tacrolimus in Kidney Transplantation: A Retrospective Real-World Data Analysis
Wilfried Gwinner 1ABDE* , Swapneel Anaokar 2ACDE , Martin Blogg 2ACDE , Birgit Hermann 3ACDE , Carola del Pilar Repetur 2CDE , Mario Schiffer 4ABDEDOI: 10.12659/AOT.942167
Ann Transplant 2024; 29:e942167
Table 5 Sensitivity analysis of primary endpoint: Kaplan-Meier estimates of the individual components of the composite endpoint stratified by population cohort (first 5 years post-transplant).
KM rate estimate (95% CI) | Year | Cohort | |||
---|---|---|---|---|---|
De novo (n=101) | Early conversion (n=12) | Late conversion (n=50) | Full analysis (N=163) | ||
Graft loss | 1 | 0.959 (0.895–0.985) | 1.000 (1.000–1.000) | 1.000 (1.000–1.000) | 0.975 (0.935–0.991) |
2 | 0.927 (0.852–0.964) | 0.917 (0.539–0.988) | 0.980 (0.866–0.997) | 0.943 (0.892–0.970) | |
3 | 0.916 (0.838–0.957) | 0.917 (0.539–0.988) | 0.960 (0.848–0.990) | 0.929 (0.876–0.960) | |
4 | 0.868 (0.778–0.923) | 0.917 (0.539–0.988) | 0.939 (0.822–0.980) | 0.894 (0.832–0.934) | |
5 | 0.842 (0.748–0.904) | 0.815 (0.435–0.951) | 0.912 (0.780–0.966) | 0.862 (0.794–0.909) | |
BCAR | 1 | 0.818 (0.726–0.881) | 0.583 (0.270–0.801) | 0.740 (0.595–0.840) | 0.775 (0.702–0.832) |
2 | 0.759 (0.660–0.833) | 0.583 (0.270–0.801) | 0.720 (0.574–0.824) | 0.734 (0.658–0.797) | |
3 | 0.759 (0.660–0.833) | 0.583 (0.270–0.801) | 0.720 (0.574–0.824) | 0.734 (0.658–0.797) | |
4 | 0.733 (0.630–0.812) | 0.583 (0.270–0.801) | 0.720 (0.574–0.824) | 0.719 (0.641–0.783) | |
5 | 0.733 (0.630–0.812) | 0.583 (0.270–0.801) | 0.720 (0.574–0.824) | 0.719 (0.641–0.783) | |
Graft dysfunction | 1 | 0.780 (0.686–0.850) | 0.750 (0.408–0.912) | 0.900 (0.776–0.957) | 0.815 (0.746–0.867) |
2 | 0.769 (0.674–0.840) | 0.750 (0.408–0.912) | 0.900 (0.776–0.957) | 0.808 (0.739–0.861) | |
3 | 0.746 (0.648–0.821) | 0.750 (0.408–0.912) | 0.880 (0.751–0.944) | 0.788 (0.716–0.844) | |
4 | 0.723 (0.622–0.801) | 0.667 (0.337–0.860) | 0.880 (0.751–0.944) | 0.767 (0.693–0.826) | |
5 | 0.710 (0.608–0.791) | 0.667 (0.337–0.860) | 0.854 (0.716–0.928) | 0.752 (0.676–0.812) | |
BCAR – biopsy-confirmed acute rejection; CI – confidence interval; KM – Kaplan-Meier. The KM estimates of individual components are presented only as a sensitivity analysis of the primary endpoint owing to potential bias due to the competing risks of occurrence of the other primary endpoint components. |